Benefits And Risks Of Increasing Restrictions On Access To Costly Drugs In Medicaid
Author:
- 1 January 2004
- journal article
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 23 (1) , 135-146
Abstract
States are reacting to increased Medicaid drug costs by implementing cost-control policies, such as preferred drug lists (PDLs) and prior authorization. PDLs have risks as well as benefits. Targeti...Keywords
This publication has 14 references indexed in Scilit:
- Reference Pricing For Drugs: Is It Compatible With U.S. Health Care?Health Affairs, 2003
- Health Services Utilization With Reference Drug Pricing of Histamine2 Receptor Antagonists in British Columbia ElderlyMedical Care, 2002
- Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme InhibitorsNew England Journal of Medicine, 2002
- Prior Authorization Programs: A Critical Review of the LiteratureJournal of Managed Care Pharmacy, 2001
- Utilization of Essential Medications by Vulnerable Older People After a Drug Benefit Cap: Importance of Mental Disorders, Chronic Pain, and Practice SettingJournal of the American Geriatrics Society, 2001
- Computer-Based Drug-Utilization Review — Risk, Benefit, or Boondoggle?New England Journal of Medicine, 1995
- Effect of a Prior-Authorization Requirement on the Use of Nonsteroidal Antiinflammatory Drugs by Medicaid PatientsNew England Journal of Medicine, 1995
- Withdrawing Payment for Nonscientific Drug TherapyJAMA, 1990
- Cost Effects of Restricting Cost-effective TherapyMedical Care, 1985
- SURGICAL TREATMENT OF PEPTIC ULCER IN THE UNITED STATESThe Lancet, 1981